JNJ-26483327

· Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-26483327, covering 2010-04-26 to 2010-04-26. Get the full timeline:

Most recent: Clinical Trial Update: A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies. [Phase 1]

See pricing